Stockhub

Jiangsu Hengrui Medicine Co., Ltd.

Page Discussion
Revision as of 09:35, 27 September 2022 by 95.149.241.133 (talk) (Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Summary[1]Edit

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.

References and notesEdit

  1. ↑ Source: Yahoo Finance.
Retrieved from ‘https://stockhub.co/index.php?title=Jiangsu_Hengrui_Medicine_Co.,_Ltd.&oldid=77690’